Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

PURPOSE: CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ciprotti, Marika, Tebbutt, Niall C., Lee, Fook-Thean, Lee, Sze-Ting, Gan, Hui K., McKee, David C., O'Keefe, Graeme J., Gong, Sylvia J., Chong, Geoffrey, Hopkins, Wendie, Chappell, Bridget, Scott, Fiona E., Brechbiel, Martin W., Tse, Archie N., Jansen, Mendel, Matsumura, Manabu, Kotsuma, Masakatsu, Watanabe, Rira, Venhaus, Ralph, Beckman, Robert A., Greenberg, Jonathan, Scott, Andrew M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881374/
https://ncbi.nlm.nih.gov/pubmed/26124477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.4256
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados